The author makes the point that the vast attention paid to failure to disclose is misplaced, and that more attention must be focused on the financial conflicts themselves and their consequences. He avers that the best approach to financial conflicts is to have none, and that those individuals who are free of financial ties to industry should be the ones appointed to major decision-making roles in journals, clinical practice guideline committees, FDA panels, and professional societies. 